Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Macrogenics Inc patents


Recent patent applications related to Macrogenics Inc. Macrogenics Inc is listed as an Agent/Assignee. Note: Macrogenics Inc may have other listings under different names/spellings. We're not affiliated with Macrogenics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Macrogenics Inc-related inventors


Covalent diabodies and uses thereof

The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. ... Macrogenics Inc

Antibodies reactive with b7-h3 and uses thereof

The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.. ... Macrogenics Inc

Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof

The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of cd3 and one binding site specific for an epitope of gpa33 (i.e., a “gpa33×cd3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin fc domain (“bi-specific monovalent fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpa33 and one binding site specific for an epitope of cd3 (i.e., a “gpa33×cd3 bi-specific monovalent fc diabody”). ... Macrogenics Inc

Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof

The present invention is directed to sequence-optimized cd123×cd3 bi-specific monovalent diabodies that are capable of simultaneous binding to cd123 and cd3, and to the uses of such diabodies in the treatment of hematologic malignancies.. . ... Macrogenics Inc

Combination of fcgammariib-specific antibodies and cd20-specific antibodies and methods of use thereof

The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with cd20 expression that encompass administration of a combination of: (a) one or more antibodies that specifically bind fcγriib, particularly human fcγriib, with greater affinity than said antibodies bind fcγriia, and (b) one or more antibodies that specifically bind to cd20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a b cell related disease or disorder or an inflammatory disorder. ... Macrogenics Inc

Bcr-complex-specific antibodies and methods of using same

This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.. ... Macrogenics Inc

Multivalent molecules comprising dr5-binding domains

The present invention is directed to multivalent dr5-binding molecules that comprise binding domain(s) of anti-dr5 antibodies, and particularly binding domain(s) of anti-human dr5 antibodies. The dr5-binding molecules of the present invention include bivalent and tetravalent molecules having two, three or four dr5-binding domains each capable of binding human dr5. ... Macrogenics Inc

Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting

The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease).. ... Macrogenics Inc

Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof

The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.. ... Macrogenics Inc

Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Cd 19×cd3 bi-specific monovalent diabodies, and particularly, cd 19×cd3 bi-specific monovalent fc diabodies, are capable of simultaneous binding to cd 19 and cd3, and are used in the treatment of hematologic malignancies.. . ... Macrogenics Inc

Ror1-binding molecules, and methods of use thereof

The present invention is directed to optimized ror1-binding molecules having enhanced affinity and superior ability to mediate redirected cytotoxicity of tumor cells relative to prior ror1-binding molecules. More specifically, the invention relates to optimized ror1-binding molecules that comprise variable light chain and/or variable heavy chain (vh) domains that have been optimized for binding to an epitope present on the human ror1 polypeptide so as to exhibit enhanced binding affinity for human ror1 and/or a reduced immunogenicity upon administration to recipient subjects. ... Macrogenics Inc

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.. ... Macrogenics Inc

Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof

The present invention relates to tri-specific binding molecules, which are multi-chain polypeptide molecules that possess three binding domains and are thus capable of mediating coordinated binding to three epitopes. The tri-specific binding molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first cancer antigen, (2) an epitope of a second cancer antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a cancer antigen, so as to thereby facilitate the killing of such cancer cell.. ... Macrogenics Inc

Tri-specific binding molecules and methods of use thereof

The present invention relates to tri-specific binding molecules, which are multichain polypeptide molecules that possess three binding domains and are thus capable of mediating coordinated binding to three epitopes. The binding domains may be selected such that the tri-specific binding molecules are capable of binding to any three different epitopes. ... Macrogenics Inc

07/13/17 / #20170198037

Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof

The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one epitope-binding site that is immunospecific for an epitope of pd-1 and at least one epitope-binding site that is immunospecific for an epitope of lag-3 (i.e., a “pd-i×lag-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two epitope-binding sites that are immunospecific for one (or two) epitope(s) of pd-1 and two epitope-binding site that are immunospecific for one (or two) epitope(s) of lag-3 (i.e., a “pd-1×lag-3 bi-specific, tetra-valent diabody”).. ... Macrogenics Inc

06/08/17 / #20170157251

Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

The present invention is directed to a combination therapy involving the administration of: (1) a bi-specific molecule capable of specifically binding to cd19 and to cd3 (i.e., a cd19×cd3 bi-specific molecule), and (2) a bruton's tyrosine kinase (btk) inhibitor for the treatment of disease, in particular treatment of a disease associated with or characterized by the expression of cd19. Preferably, such a cd19×cd3 bi-specific molecules are bi-specific monovalent diabodies. ... Macrogenics Inc

05/18/17 / #20170137519

Cd3-binding molecules capable of binding to human and non-human cd3

The present invention relates to cd3-binding molecules capable of binding to human and non-human cd3, and in particular to such molecules that are cross-reactive with cd3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.. ... Macrogenics Inc

01/26/17 / #20170022294

Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

The disclosure relates to compounds specific for il23a and baff, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.. ... Macrogenics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Macrogenics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Macrogenics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###